Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8722650	BAUSCH	Extended-release minocycline dosage forms	Jun, 2025 (1 year, 8 months from now)
US8252776	BAUSCH	Minocycline oral dosage forms for the treatment of acne	Jun, 2025 (1 year, 8 months from now)
US8268804	BAUSCH	Minocycline oral dosage forms for the treatment of acne	Jun, 2025 (1 year, 8 months from now)
US7790705	BAUSCH	Minocycline oral dosage forms for the treatment of acne	Jun, 2025 (1 year, 8 months from now)
US7919483	BAUSCH	Method for the treatment of acne	Mar, 2027 (3 years from now)
US7544373	BAUSCH	Minocycline oral dosage forms for the treatment of acne	Apr, 2027 (3 years from now)
US7541347	BAUSCH	Minocycline oral dosage forms for the treatment of acne	Apr, 2027 (3 years from now)
US9192615	BAUSCH	Method for the treatment of acne and certain dosage forms thereof	Nov, 2031 (8 years from now)

Solodyn is owned by Bausch.

Solodyn contains Minocycline Hydrochloride.

Solodyn has a total of 8 drug patents out of which 0 drug patents have expired.

Solodyn was authorised for market use on 08 May, 2006.

Solodyn is available in tablet, extended release;oral dosage forms.

Solodyn can be used as treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris, treatment of acne.

The generics of Solodyn are possible to be released after 17 November, 2031.

Market Authorisation Date: 08 May, 2006

Treatment: Treatment of acne; Treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
45 mg, 90 mg and 135 mg
55 mg	02 Dec, 2010	1	30 Nov, 2011	20 Nov, 2025	Eligible
65 mg and 115 mg	19 Nov, 2009	1	18 May, 2012	19 Feb, 2018	Extinguished Eligible
80 mg	27 Oct, 2010	1	25 Sep, 2014	19 Feb, 2018	Non-Forfeiture
105 mg	13 Dec, 2010	1		19 Feb, 2018	Non-Forfeiture

Strength	Dosage	Availability
EQ 45MG BASE	TABLET, EXTENDED RELEASE;ORAL	Discontinued
EQ 55MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 65MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 80MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 90MG BASE	TABLET, EXTENDED RELEASE;ORAL	Discontinued
EQ 105MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 115MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 135MG BASE	TABLET, EXTENDED RELEASE;ORAL	Discontinued

SOLODYN family patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic